Utilization and Costs of Medications Associated With CKD Mineral and Bone Disorder in Dialysis Patients Enrolled in Medicare Part D

Part D net costs for CKD-MBD medications increased at a faster rate than costs for all Part D medications in dialysis patients despite relatively stable use within medication classes. In a bundled environment, there may be incentives to shift to generic phosphate binders and reduce cinacalcet use.